Taking a “Development-by-Design” Approach to Cell Therapies

Publication
Article
BioPharm InternationalBioPharm International-06-15-2015
Volume 2015 eBook
Issue 1

Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, cost of goods, and sustainability from the start.

Cell therapies, both autologous and allogeneic, have come a long way in just a few years. Failures, often in clinical stages, have been traced to problems with manufacturing and failure to understand process requirements earlier in the development process.

 

Download

BioPharm International’s 2015 Outsourcing Resources eBook

.

 

 

 

 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content
© 2025 MJH Life Sciences

All rights reserved.